Results 51 to 60 of about 1,259,702 (421)
Have advances in medical therapy for ulcerative colitis impacted surgical treatment?
Annals of Gastroenterological Surgery, 2023 Aim The purpose of this study was to examine how the clinical characteristics, indications for surgery, and postoperative course of ulcerative colitis (UC) surgical patients changed before and after the introduction of biological agents. Methods Patients
Ryuichi Kuwahara +5 more
doaj +1 more source
The burden of inflammatory bowel disease in Europe in 2020.
Journal of Crohn's & Colitis, 2021 New data suggest that incidence and prevalence of inflammatory bowel diseases (IBD) are still increasing worldwide, and approximately 0.2% of the European population suffers from IBD at the present time.
Mirabella Zhao +3 more
semanticscholar +1 more source
The natural history of primary sclerosing cholangitis in 781 children. A multicenter, international collaboration [PDF]
, 2017 There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC.
Abdou, Reham +45 more
core +7 more sources
Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study [PDF]
Intestinal Research, 2022 Background/Aims Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed in patients younger than 6 years, is a challenge for pediatric gastroenterologists.
Masaaki Usami +8 more
doaj +1 more source
Gastroenterology, 2004 Although the incidence and prevalence of ulcerative colitis and Crohn's disease are beginning to stabilize in high-incidence areas such as northern Europe and North America, they continue to rise in low-incidence areas such as southern Europe, Asia, and ...
E. Loftus
semanticscholar +1 more source
Scientific Reports, 2021 Intestinal dysbiosis is key in the onset and development of Crohn’s disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects.
Laura Sanchis-Artero +11 more
doaj +1 more source
Review of the safety with biologics in inflammatory bowel disease
Journal of IMIDs, 2022 Biologics have completely changed the treatment (and life) of patients with inflammatory bowel disease (IBD). After the first ones, anti-tumor necrosis factor (TNF) biologics, two new biologics, with other therapeutic targets, are now in routine use in ...
Andrea Pascual +3 more
doaj +1 more source
Gut microbiome structure and metabolic activity in inflammatory bowel disease
Nature Microbiology, 2018 The inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract.
E. Franzosa +26 more
semanticscholar +1 more source
Understanding the health and social care needs of people living with IBD: A meta-synthesis of the evidence [PDF]
, 2012 AIM: To undertake a metasynthesis of qualitative studies to understand the health and social needs of people living with inflammatory bowel disease (IBD).
Griffiths, Jane +2 more
core +1 more source
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Genome Biology, 2012 The inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis result from alterations in intestinal microbes and the immune system. However, the precise dysfunctions of microbial metabolism in the gastrointestinal microbiome during IBD ...
X. Morgan +14 more
semanticscholar +1 more source